

10/771,696

-2-

PC9985B

Amendments to the Claims:


Claims 1-12 (Canceled)

Claims 13-25 (Canceled)

26. (Canceled)

27. (Canceled)

28. (Currently AmendedNew) A method for the treatment of a disorder or condition mediated by an EP4 receptor in a mammalian subject including a human, wherein the disorder or condition is selected from pain, inflammation, an inflammation associated disorder, osteoarthritis, and rheumatoid arthritis, said method comprising administering to a mammal in need of such treatment an effective amount of a compound of the following formula:



(I)

or the pharmaceutically acceptable salts thereof, wherein  
one of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> is N and the others are independently selected from CH and  
C(L);

R<sup>1</sup> is H, C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, C<sub>1-8</sub> alkoxy, halo-substituted C<sub>1-8</sub> alkoxy, C<sub>1-8</sub> alkyl-S(O)m-, Q<sup>1</sup>-, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, amino, mono- or di-(C<sub>1-8</sub> alkyl)amino, C<sub>1-4</sub>alkyl-C(=O)-N(R<sup>3</sup>)- or C<sub>1-4</sub>alkyl-S(O)m-N(R<sup>3</sup>)-, wherein said C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl

10/771,696

-3-

PC9985B

and C<sub>2-8</sub> alkynyl are optionally substituted with halo, C<sub>1-3</sub> alkyl, hydroxy, oxo, C<sub>1-4</sub> alkoxy-, C<sub>1-4</sub> alkyl-S(O)m-, C<sub>3-7</sub> cycloalkyl-, cyano, indanyl, 1,2,3,4-tetrahydronaphthyl, 1,2-dihydronaphthyl, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, Q<sup>1</sup>-, Q<sup>1</sup>-C(=O)-, Q<sup>1</sup>-O-, Q<sup>1</sup>-S(O)m-, Q<sup>1</sup>-C<sub>1-4</sub>alkyl-O-, Q<sup>1</sup>-C<sub>1-4</sub>alkyl-S(O)m-, Q<sup>1</sup>-C<sub>1-4</sub>alkyl-C(O)-N(R<sup>3</sup>)-, Q<sup>1</sup>-C<sub>1-4</sub>alkyl-N(R<sup>3</sup>)- or C<sub>1-4</sub>alkyl-C(O)-N(R<sup>3</sup>)-;

Q<sup>1</sup> is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, and is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, nitro, amino, mono- or di-(C<sub>1-4</sub>alkyl)amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub>alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub>alkylC(=O)-, HO(O=)C-, C<sub>1-4</sub>alkyl-O(O=)C-, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, R<sup>3</sup>C(=O)N(R<sup>4</sup>)- or NH<sub>2</sub>(HN=)C-;

A is a 5-6 membered monocyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, wherein said 5-6 membered monocyclic aromatic ring is optionally substituted with up to 3 substituents selected from halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, nitro, amino, mono- or di-(C<sub>1-4</sub> alkyl)amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub>alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, acetyl, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, HO(O=)C-, C<sub>1-4</sub>alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, R<sup>3</sup>C(=O)N(R<sup>4</sup>)- and NH<sub>2</sub>(HN=)C-;

B is halo-substituted C<sub>1-6</sub> alkylene, C<sub>3-7</sub> cycloalkylene, C<sub>2-6</sub> alkenylene, C<sub>2-6</sub> alkynylene, -O-C<sub>1-5</sub> alkylene, C<sub>1-2</sub> alkylene-O-C<sub>1-2</sub> alkylene or C<sub>1-6</sub> alkylene optionally substituted with an oxo group or C<sub>1-3</sub> alkyl;

W is NH, N-C<sub>1-4</sub> alkyl, O, S, N-OR<sup>5</sup> or a covalent bond;

R<sup>2</sup> is H, C<sub>1-4</sub> alkyl, OH or C<sub>1-4</sub> alkoxy;

10/771,696

-4-

PC9985B

Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from O, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, C<sub>4</sub>C<sub>2-4</sub> alkenyl, C<sub>4</sub>C<sub>2-4</sub> alkynyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, nitro, amino, mono- or di-(C<sub>1-4</sub> alkyl)amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub>alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub>alkylC(=O)-, R<sup>3</sup>C(=O)N(R<sup>4</sup>)-, HO(O=)C-, C<sub>1-4</sub>alkyl-O(O=)C-, C<sub>1-4</sub>alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, NH<sub>2</sub>(HN=)C-, Q<sup>2</sup>-S(O)m-, Q<sup>2</sup>-O-, Q<sup>2</sup>-N(R<sup>3</sup>)- or Q<sup>2</sup>-;

L is halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, nitro, amino, mono- or di-(C<sub>1-4</sub> alkyl)amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub>alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub>alkylC(=O)-, HO(O=)C-, C<sub>1-4</sub>alkyl-O(O=)C-, C<sub>1-4</sub>alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, R<sup>3</sup>C(=O)N(R<sup>4</sup>)-, NH<sub>2</sub>(HN=)C-, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, R<sup>3</sup>N(R<sup>4</sup>)S(O)m-, Q<sup>2</sup>-, Q<sup>2</sup>-C(=O)-, Q<sup>2</sup>-O-, Q<sup>2</sup>-C<sub>1-4</sub>alkyl-O-, or two adjacent L groups are optionally joined together to form an alkylene chain having 3 or 4 members in which one or two (non-adjacent) carbon atoms are optionally replaced by oxygen atoms;

m is 0, 1 or 2;

R<sup>3</sup> and R<sup>4</sup> are independently selected from H and C<sub>1-4</sub> alkyl ;

R<sup>5</sup> is H, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkyl-(O=)C- or C<sub>1-4</sub> alkyl-O-(O=)C- ; and

Q<sup>2</sup> is a 5-12 membered monocyclic or bicyclic aromatic ring, or a 5-12 membered tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, nitro, amino, mono- or di-(C<sub>1-4</sub> alkyl)amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub>

10/771,696

-5-

PC9985B

4alkyl, C<sub>1</sub>-4 alkylsulfonyl, aminosulfonyl, C<sub>1</sub>-4alkyl- (O=)C-, R<sup>3</sup>(R<sup>4</sup>)C(=O)N-, HO(O=)C-, C<sub>1</sub>-4 alkyl-O(O=)C-, C<sub>1</sub>-4 alkylsulfonylamino, C<sub>3</sub>-7 cycloalkyl, C<sub>1</sub>-4 alkyl-C(=O)NH- or NH<sub>2</sub>(HN=)C-.

29. (Currently Amended) A method according to Claim 28, wherein

one of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup>, and Y<sup>4</sup> is N and the others are independently selected from CH and C(L);

R<sup>1</sup> is H, C<sub>1</sub>-8 alkyl, C<sub>2</sub>-8 alkenyl, C<sub>2</sub>-8 alkynyl, C<sub>3</sub>-7 cycloalkyl, C<sub>1</sub>-8 alkoxy, halo-substituted C<sub>1</sub>-8 alkoxy, C<sub>1</sub>-8 alkyl-S(O)m-, Q<sup>1</sup>-, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, amino, mono- or di-(C<sub>1</sub>-8 alkyl)amino, C<sub>1</sub>-4alkyl-C(=O)-N(R<sup>3</sup>)- or C<sub>1</sub>-4alkyl-S(O)m-N(R<sup>3</sup>)-, wherein said C<sub>1</sub>-8 alkyl, C<sub>2</sub>-8 alkenyl and C<sub>2</sub>-8 alkynyl are optionally substituted with halo, C<sub>1</sub>-3 alkyl, hydroxy, oxo, C<sub>1</sub>-4 alkoxy-, C<sub>1</sub>-4 alkyl-S(O)m-, C<sub>3</sub>-7 cycloalkyl-, cyano, indanyl, 1,2,3,4-tetrahydronaphthyl, 1,2-dihydronaphthyl, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, Q<sup>1</sup>-, Q<sup>1</sup>-C(=O)-, Q<sup>1</sup>-O-, Q<sup>1</sup>-S(O)m-, Q<sup>1</sup>-C<sub>1</sub>-4 alkyl-O-, Q<sup>1</sup>-C<sub>1</sub>-4 alkyl-S(O)m-, Q<sup>1</sup>-C<sub>1</sub>-4alkyl-C(=O)-N(R<sup>3</sup>)-, or C<sub>1</sub>-4alkyl-C(=O)-N(R<sup>3</sup>)-;

Q<sup>1</sup> is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 4 heteroatoms selected from O, N and S, and is optionally substituted with halo, C<sub>1</sub>-4 alkyl, halo-substituted C<sub>1</sub>-4 alkyl , hydroxy, C<sub>1</sub>-4 alkoxy, halo-substituted C<sub>1</sub>-4 alkoxy, C<sub>1</sub>-4 alkylthio, nitro, amino, mono- or di-(C<sub>1</sub>-4 alkyl)amino, cyano, HO-C<sub>1</sub>-4 alkyl, C<sub>1</sub>-4 alkoxy-C<sub>1</sub>-4alkyl, C<sub>1</sub>-4 alkylsulfonyl, aminosulfonyl, C<sub>1</sub>-4 alkylC(=O)-, HO(O=)C-, C<sub>1</sub>-4 alkyl-O(O)C-, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, C<sub>1</sub>-4 alkylsulfonylamino, C<sub>3</sub>-7 cycloalkyl, R<sup>3</sup>C(=O)N(R<sup>4</sup>)- or NH<sub>2</sub>(HN=)C-;

A is a 5-6 membered monocyclic aromatic ring optionally containing up to 2 heteroatoms selected from O, N, and S, wherein said 5-6 membered monocyclic aromatic ring is optionally substituted with up to 2 substituents selected from halo,

10/771,696

-6-

PC9985B

C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy and halo-substituted C<sub>1-4</sub> alkoxy;

B is C<sub>3-7</sub> cycloalkylene or C<sub>1-6</sub> alkylene optionally substituted with an oxo group or C<sub>1-3</sub> alkyl;

W is NH, N-C<sub>1-4</sub> alkyl, O or N-OH;

R<sup>2</sup> is H or C<sub>1-4</sub> alkyl;

Z is a 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, C<sub>4</sub>C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, hydroxy, C<sub>1-4</sub> alkoxy, nitro, amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub> alkylC(=O)-, R<sup>3</sup>C(=O)N(R<sup>4</sup>)-, HO(O=)C-, C<sub>1-4</sub> alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>1-4</sub> alkyl-C(=O)NH-, Q<sup>2</sup>-S(O)m-, Q<sup>2</sup>-O-, Q<sup>2</sup>-N(R<sup>3</sup>)- or Q<sup>2</sup>-;

L is halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, mono- or di-(C<sub>1-4</sub> alkyl)amino, halo-substituted C<sub>1-4</sub> alkoxy, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub> alkylC(=O)-, HO(O=)C-, C<sub>1-4</sub> alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, R<sup>3</sup>C(=O)N(R<sup>4</sup>)-, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, R<sup>3</sup>N(R<sup>4</sup>)S(O)m-, Q<sup>2</sup>-, Q<sup>2</sup>-C(=O)-, Q<sup>2</sup>-O-, Q<sup>2</sup>-C<sub>1-4</sub> alkyl-O-, or two adjacent L groups are optionally joined together to form an alkylene chain having 3 or 4 members in which one or two (non-adjacent) carbon atoms are optionally replaced by oxygen atoms;

m is 0 or 2;

R<sup>3</sup> and R<sup>4</sup> are independently selected from H and C<sub>1-4</sub> alkyl; and

Q<sup>2</sup> is a 5-12 membered monocyclic or bicyclic aromatic ring, or a 8-12 membered tricyclic ring optionally containing up to 3 heteroatoms selected from O, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub>

10/771,696

-7-

PC9985B

alkynyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, C<sub>1-4</sub> alkylthio, mono- or di-(C<sub>1-4</sub> alkyl)amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub> alkyl-(O=)C-, R<sup>3</sup>(R<sup>4</sup>)C(=O)N-, HO(O=)C-, C<sub>1-4</sub> alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl or C<sub>1-4</sub> alkyl-C(=O)NH-.

30. (Previously Presented) A method according to Claim 29, wherein one of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup>, and Y<sup>4</sup> is N and the others are independently selected from CH and C(L);
- R<sup>1</sup> is H, C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl, C<sub>3-7</sub> cycloalkyl, Q<sup>1</sup>-, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, amino, mono- or di-(C<sub>1-8</sub> alkyl)amino, wherein said C<sub>1-8</sub> alkyl is optionally substituted with halo, C<sub>1-3</sub> alkyl, hydroxy, oxo, C<sub>1-4</sub> alkoxy-, C<sub>1-4</sub> alkyl-S(O)m-, C<sub>3-7</sub> cycloalkyl-, cyano, indanyl, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, Q<sup>1</sup>-, Q<sup>1</sup>-C(O)-, Q<sup>1</sup>-O-, Q<sup>1</sup>-S-, Q<sup>1</sup>-C<sub>1-4</sub> alkyl-O-, or C<sub>1-4</sub> alkyl-C(O)-N(R<sup>3</sup>)-;
- Q<sup>1</sup> is a 5-12 membered monocyclic aromatic ring optionally containing up to 4 heteroatoms selected from N and S, and is optionally substituted with halo, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulfonyl and C<sub>1-4</sub> alkylC(=O)-;
- A is 5-6 membered monocyclic aromatic ring optionally substituted with halo, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy;
- B is C<sub>3-7</sub> cycloalkylene or C<sub>1-6</sub> alkylene optionally substituted with an oxo group or C<sub>1-3</sub> alkyl;
- W is NH, N-C<sub>1-4</sub> alkyl, O or N-OH;
- R<sup>2</sup> is H or C<sub>1-4</sub> alkyl;
- Z is 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from, N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-

10/771,696

-8-

PC9985B

substituted C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>1-4</sub> alkoxy, nitro, amino, cyano, R<sup>3</sup>C(=O)N(R<sup>4</sup>)-, C<sub>1-4</sub> alkyl-O(O=)C-, Q<sup>2-</sup>S(O)m-, Q<sup>2-</sup>O-, Q<sup>2-</sup>N(R<sup>3</sup>)- or Q<sup>2-</sup>; L is halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, mono- or di-(C<sub>1-4</sub> alkyl)amino, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub> alkylC(=O)-, HO(O=)C-, C<sub>1-4</sub> alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, R<sup>3</sup>C(=O)N(R<sup>4</sup>)-, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, R<sup>3</sup>N(R<sup>4</sup>)S(O)m-, Q<sup>2-</sup>, Q<sup>2-</sup>C(=O)-, Q<sup>2-</sup>O-, Q<sup>2-</sup>C<sub>1-4</sub>alkyl-O-, or two adjacent L groups are optionally joined together to form an alkylene chain having 3 or 4 members in which one or two (non-adjacent) carbon atoms are optionally replaced by oxygen atoms;

m is 0 or 2;

R<sup>3</sup> and R<sup>4</sup> are independently selected from H and C<sub>1-4</sub> alkyl; and

Q<sup>2</sup> is a 5 or 6 membered monocyclic aromatic ring, or a 8-12 membered tricyclic ring containing up to 3 heteroatoms selected from N and S, wherein said 5 or 6 membered monocyclic aromatic ring is optionally substituted with halo.

31. (Previously Presented) A method according to Claim 30, wherein

one of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> is N and the others are independently selected from CH and C(L);

R<sup>1</sup> is H, C<sub>1-8</sub> alkyl, C<sub>2-8</sub> alkenyl, C<sub>2-8</sub> alkynyl or C<sub>3-7</sub> cycloalkyl, wherein said C<sub>1-8</sub> alkyl is optionally substituted with halo, C<sub>1-3</sub> alkyl, hydroxy, oxo, C<sub>1-4</sub> alkoxy-, C<sub>1-4</sub> alkyl-S(O)m-, C<sub>3-7</sub> cycloalkyl-, cyano, indanyl, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, Q<sup>1-</sup>, Q<sup>1-</sup>C(=O)-, Q<sup>1-</sup>O-, Q<sup>1-</sup>S-, Q<sup>1-</sup>C<sub>1-4</sub> alkyl-O-, or C<sub>1-4</sub>alkyl-C(O)-N(R<sup>3</sup>)-;

Q<sup>1</sup> is a 5 or 6 membered monocyclic aromatic ring optionally containing up to 4 heteroatoms selected from N and S;

10/771,696

-9-

PC9985B

A is 5-6 membered monocyclic aromatic ring system optionally substituted with halo or C<sub>1-4</sub> alkyl;

B is C<sub>3-7</sub> cycloalkylene or C<sub>1-6</sub> alkylene optionally substituted with an oxo group or C<sub>1-3</sub> alkyl;

W is NH, N-C<sub>1-4</sub> alkyl, O or N-OH;

R<sup>2</sup> is H or C<sub>1-4</sub> alkyl;

Z is 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from N and S, wherein said 5-12 membered monocyclic or bicyclic aromatic ring is optionally substituted with halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, C<sub>2-4</sub> alkenyl, C<sub>1-4</sub> alkoxy, nitro, amino, cyano,

R<sup>3</sup>C(=O)N(R<sup>4</sup>)-, C<sub>1-4</sub> alkyl-O(O=)C-, Q<sup>2</sup>-S(O)m-, Q<sup>2</sup>-O-, Q<sup>2</sup>-N(R<sup>3</sup>)- or Q<sup>2</sup>-;

L is halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, cyano, HO-C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkylsulfonyl, aminosulfonyl, C<sub>1-4</sub> alkylC(=O), HO(O=)C-, C<sub>1-4</sub> alkyl-O(O=)C-, C<sub>1-4</sub> alkylsulfonylamino, C<sub>3-7</sub> cycloalkyl, R<sup>3</sup>C(=O)NR<sup>4</sup>-, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, R<sup>3</sup>N(R<sup>4</sup>)S(O)m-, Q<sup>2</sup>-, Q<sup>2</sup>-C(=O)-, Q<sup>2</sup>-O-, Q<sup>2</sup>-C<sub>1-4</sub>alkyl-O-, or two adjacent L groups are optionally joined together to form an alkylene chain having 3 or 4 members in which one or two (non-adjacent) carbon atoms are optionally replaced by oxygen atoms;

m is 0 or 2;

R<sup>3</sup> and R<sup>4</sup> are independently selected from H and C<sub>1-4</sub> alkyl; and

Q<sup>2</sup> is 5 or 6 membered monocyclic aromatic ring or a 8-12 membered tricyclic ring optionally containing 1 sulfur atom wherein said 5 or 6 membered monocyclic aromatic ring is optionally substituted with halo.

32. (Previously Presented) A method according to Claim 31, wherein

one of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> is N and the others are independently selected from CH and C(L);

10/771,696

-10-

PC9985B

R<sup>1</sup> is C<sub>1-5</sub> alkyl or C<sub>3-7</sub> cycloalkyl, wherein said C<sub>1-5</sub> alkyl is optionally substituted with C<sub>1-3</sub> alkyl, hydroxy, oxo, pyrrolidinyl, piperidyl, oxopyrrolidinyl, oxopiperidyl, Q<sup>1-</sup>, or C<sub>1-4</sub>alkyl-C(O)-N(H)-;

Q<sup>1</sup> is 5-12 membered monocyclic aromatic ring system optionally containing up to 2 heteroatoms selected from N and S,

A is 5-6 membered monocyclic aromatic ring system;

B is C<sub>1-3</sub> alkylene optionally substituted with C<sub>1-3</sub> alkyl;

W is NH, N-C<sub>1-2</sub> alkyl or O;

R<sup>2</sup> is H;

Z is 5-12 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from N and S, wherein said 5-12 membered monocyclic aromatic ring is optionally substituted with halo, C<sub>1-4</sub> alkyl, nitro, R<sup>3</sup>C(=O)N(R<sup>4</sup>)- or Q<sup>2-</sup>;

L is halo, C<sub>1-4</sub> alkyl, halo-substituted C<sub>1-4</sub> alkyl, hydroxy, C<sub>1-4</sub> alkoxy, halo-substituted C<sub>1-4</sub> alkoxy, cyano, HO-C<sub>1-4</sub> alkyl, acetyl, R<sup>3</sup>N(R<sup>4</sup>)C(=O)-, R<sup>3</sup>N(R<sup>4</sup>)S(O)m-, Q<sup>2-</sup>, Q<sup>2-</sup>C(=O)-, or two adjacent L groups are joined together to form a methylenedioxy group;

R<sup>3</sup> and R<sup>4</sup> are independently selected from H and C<sub>1-4</sub> alkyl; and

Q<sup>2</sup> is 5 or 6 membered monocyclic aromatic ring system.

33. (Currently Amended) A method according to Claim 32, wherein

one of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> is N and the others are independently selected from CH and C(L);

R<sup>1</sup> is C<sub>1-5</sub> alkyl optionally substituted with C<sub>1-3</sub> alkyl, hydroxy, oxo, 5 or 6 membered monocyclic aromatic ring, wherein said 5 or 6 membered monocyclic aromatic ring is containing 1 or 2 heteroatoms selected from N and S, or C<sub>1-4</sub>alkyl-C(O)-N(R<sup>3</sup>)-;

A is phenyl;

10/771,696

-11-

PC9985B

B is C<sub>1-2</sub> alkylene optionally substituted with methyl;

W is NH, N-CH<sub>3</sub> or O;

R<sup>2</sup> is H;

Z is 5-10 membered monocyclic or bicyclic aromatic ring optionally containing up to 3 heteroatoms selected from N and S, wherein said 5-10 membered monocyclic aromatic ring is optionally substituted with chloro, bromo, methyl, nitro, CH<sub>3</sub>C(=O)NH-, tBuC(=O)NH- or phenyl; and

L is chloro, methyl, trifluoromethyl, hydroxy, methoxy, cyano, acetyl, -C(=O)NH<sub>2</sub>, trifluoromethoxy, methanesulfonyl, or 1-hydroxy-1-methyl-ethyl, or two adjacent L groups are joined together to form a methylenedioxy group.

34. (Currently Amended) A method according to Claim 33, wherein

one of Y<sup>1</sup>, Y<sup>2</sup>, Y<sup>3</sup> and Y<sup>4</sup> is N and the others are independently selected from CH and C(L);

R<sup>1</sup> is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, neopentyl, thiazolylethyl methylamino, dimethylamino, pyrrolidinyl, pyridyl, or 1-acetylamino-1-methylethyl;

A is phenyl;

B is ethylene or propylene;

W is NH, N-CH<sub>3</sub> or O;

R<sup>2</sup> is H;

Z is phenyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, naphthyl or benzothienyl, said phenyl, pyrazolyl, thiazolyl, thiadiazolyl and thienyl being optionally substituted with one to three substituents independently selected from chloro, bromo, methyl, acetylamino, pivaloylamino, nitro and phenyl; and

L is chloro, methyl, trifluoromethyl, hydroxy, methoxy, cyano, acetyl, -C(=O)NH<sub>2</sub>, trifluoromethoxy, methanesulfonyl, or 1-hydroxy-1-methyl-ethyl, or two adjacent L groups are joined together to form a methylenedioxy group.

10/771,696

-12-

PC9985B

35. (Currently Amended) A method according to Claim 34, wherein

$Y^1$ ,  $Y^2$ ,  $Y^3$  and  $Y^4$  are selected from the group consisting of

- a)  $Y^1$  and  $Y^3$  are C(L),  $Y^2$  is CH and  $Y^4$  is N;
- b)  $Y^1$  is CH,  $Y^2$  and  $Y^3$  are C(L) and  $Y^4$  is N;
- c)  $Y^1$ ,  $Y^2$  and  $Y^3$  are C(L) and  $Y^4$  is N;
- d)  $Y^1$  and  $Y^3$  are C(L),  $Y^2$  is N and  $Y^4$  is CH;
- e)  $Y^1$  and  $Y^2$  are CH,  $Y^3$  is C(L) and  $Y^4$  is N;
- f)  $Y^1$  and  $Y^3$  are CH,  $Y^2$  is C(L) and  $Y^4$  is N;
- g)  $Y^1$  and  $Y^2$  are C(L),  $Y^3$  is CH and  $Y^4$  is N;
- h)  $Y^1$  and  $Y^2$  are C(L),  $Y^3$  is N and  $Y^4$  is CH;
- i)  $Y^1$  is C(L),  $Y^2$  and  $Y^3$  are CH, and  $Y^4$  is N; and
- j)  $Y^2$  is C(L),  $Y^1$  and  $Y^3$  are CH, and  $Y^4$  is N;

$R^1$  is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, neopentyl, thiazolylethyl  
methylamino, dimethylamino, pyrrolidinyl, pyridyl, or 1-acetylamino-1-methylethyl;

A is phenyl;

B is ethylene or propylene;

W is NH, N-CH<sub>3</sub> or O;

$R^2$  is H;

Z is phenyl, pyrazolyl, thiazolyl, thiadiazolyl, thiaryl, naphthyl or benzothienyl, said  
phenyl, pyrazolyl, thiazolyl, thiadiazolyl and thiaryl being optionally substituted  
with one to three substituents independently selected from chloro, bromo, methyl,  
acetylamino, pivaloylamino, nitro and phenyl; and

L is chloro, methyl, trifluoromethyl, hydroxy, methoxy, cyano, acetyl, -C(=O)NH<sub>2</sub>,  
trifluoromethoxy, methanesulfonyl, or 1-hydroxy-1-methyl-ethyl, or two adjacent  
L groups are joined together to form a methylenedioxy group.

36. (Currently Amended) A method according to Claim 35, wherein

$Y^1$ ,  $Y^2$ ,  $Y^3$  and  $Y^4$  are selected from the group consisting of

10/771,696

-13-

PC9985B

a) Y<sup>1</sup> and Y<sup>3</sup> are C(L), Y<sup>2</sup> is CH and Y<sup>4</sup> is N;

b) Y<sup>1</sup> is CH, Y<sup>2</sup> and Y<sup>3</sup> are C(L) and Y<sup>4</sup> is N;

c) Y<sup>1</sup>, Y<sup>2</sup> and Y<sup>3</sup> are C(L) and Y<sup>4</sup> is N; and

d) Y<sup>1</sup> and Y<sup>3</sup> are C(L), Y<sup>2</sup> is N and Y<sup>4</sup> is CH;

R<sup>1</sup> is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, neopentyl, thiazolylethyl  
methylamino, dimethylamino, pyrrolidinyl, pyridyl, or 1-acetylmino-1-methylethyl;

A is phenyl;

B is ethylene or propylene;

W is NH, N-CH<sub>3</sub> or O;

R<sup>2</sup> is H;

Z is phenyl, pyrazolyl, thiazolyl, thiadiazolyl, thienyl, naphthyl or benzothienyl, said  
phenyl, pyrazolyl, thiazolyl, thiadiazolyl and thienyl being optionally substituted  
with one to three substituents independently selected from chloro, bromo, methyl,  
acetyl, pivaloyl, nitro and phenyl; and

L is chloro, methyl, trifluoromethyl, hydroxy, methoxy, cyano, acetyl, -C(=O)NH<sub>2</sub>,  
trifluoromethoxy, methanesulfonyl, or 1-hydroxy-1-methyl-ethyl, or two adjacent  
L groups are joined together to form a methylenedioxy group.

37. (Previously presented) A method according to Claim 28 wherein the compound is selected  
from

3-(4-{2-[{[(5-chloro-1,3-dimethyl-1H-pyrazol-4-  
yl)sulfonyl]amino}carbonyl]amino}ethyl} phenyl)-2-ethyl-5,7-dimethyl-3H-  
imidazo[4,5-b]pyridine;

3-(4-{2-[{[(2,4-dimethyl-1,3-thiazol-5-  
yl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-ethyl-5,7-dimethyl-3H-  
imidazo[4,5-b]pyridine;

N-[5-{{[[2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-  
yl)phenyl]ethyl}amino]carbonyl]amino}sulfonyl]-1,3,4-thiadiazol-2-yl]acetamide;  
2-ethyl-5,7-dimethyl-3-(4-{2-[methyl({[(4-methylphenyl)sulfonyl]amino}  
carbonyl]amino}ethyl}phenyl)-3H-imidazo[4,5-b]pyridine;

10/771,696

-14-

PC9985B

2-ethyl-5,7-dimethyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}propyl}phenyl)-3*H*-imidazo[4,5-*b*]pyridine;

2-[4-(2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridin-3-yl)phenyl]-1-methylethyl (4-methylphenyl)sulfonylcarbamate;

5,7-dimethyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-propyl-3*H*-imidazo[4,5-*b*]pyridine;

2-isopropyl-5,7-dimethyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-3*H*-imidazo[4,5-*b*]pyridine;

2-butyl-5,7-dimethyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-3*H*-imidazo[4,5-*b*]pyridine;

2-isobutyl-5,7-dimethyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-3*H*-imidazo[4,5-*b*]pyridine;

5,7-dimethyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-neopentyl-3*H*-imidazo[4,5-*b*]pyridine;

5,7-dimethyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-[2-(1,3-thiazol-2-yl)ethyl]-3*H*-imidazo[4,5-*b*]pyridine;

3-{4-[2-({[(4-biphenylsulfonyl)amino}carbonyl]amino}ethyl]phenyl}-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

2-ethyl-5,7-dimethyl-3-{4-[2-({[(1-naphthylsulfonyl)amino}carbonyl]amino}ethyl]phenyl}-3*H*-imidazo[4,5-*b*]pyridine;

2-ethyl-5,7-dimethyl-3-{4-[2-({[(2-naphthylsulfonyl)amino}carbonyl]amino}ethyl]phenyl}-3*H*-imidazo[4,5-*b*]pyridine;

2-ethyl-5,7-dimethyl-3-(4-{2-[{[(2-thienyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-3*H*-imidazo[4,5-*b*]pyridine;

10/771,696

-15-

PC9985B

3-(4-{2-[{[(5-chloro-2-thienyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

3-(4-{2-[{[(4,5-dichloro-2-thienyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

3-{4-[2-({[(1-benzothien-2-ylsulfonyl)amino]carbonyl}amino)ethyl]phenyl}-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

3-(4-{2-[{[(2-chlorophenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

2-ethyl-5,6-dimethyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-3*H*-imidazo[4,5-*b*]pyridine;

5,6-dichloro-2-ethyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-3*H*-imidazo[4,5-*b*]pyridine;

5-chloro-2-ethyl-7-methyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-3*H*-imidazo[4,5-*b*]pyridine;

6-cyano-2-ethyl-5,7-dimethyl-3-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-3*H*-imidazo[4,5-*b*]pyridine;

2-ethyl-4,6-dimethyl-1-(4-{2-[{[(4-methylphenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-1*H*-imidazo[4,5-*c*]pyridine;

2-ethyl-3-{4-[2-({[(3-[hydroxy(oxido)amino]phenyl}sulfonyl)amino]carbonyl}amino)ethyl]phenyl}-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

3-(4-{2-[{[(4-chlorophenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

n-[4-({[(2-[4-(2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridin-3-yl)phenyl]ethyl}amino)carbonyl]amino}sulfonyl)phenyl]-2,2-dimethylpropanamide;

10/771,696

-16-

PC9985B

3-(4-{2-[{[(2-chlorophenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

3-(4-{2-[{[(3-chlorophenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

3-(4-{2-[{[(5-chloro-2-thienyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

3-(4-{2-[{[(5-bromo-2-thienyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

3-(4-{2-[{[(2-bromophenyl)sulfonyl]amino}carbonyl]amino}ethyl}phenyl)-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

3-{4-[2-({[(4-chloro-3-nitrophenyl)sulfonyl]amino}carbonyl)amino}ethyl]phenyl}-2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridine;

2-[4-(2-ethyl-4,6-dimethyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)phenyl]ethyl (4-methylphenyl)sulfonylcarbamate;

2-{4-[5,7-dimethyl-2-(methylamino)-3*H*-imidazo[4,5-*b*]pyridin-3-yl]phenyl}ethyl (4-methylphenyl)sulfonylcarbamate;

*N*-{[(2-{4-[5,7-dimethyl-2-(methylamino)-3*H*-imidazo[4,5-*b*]pyridin-3-yl]phenyl}ethyl)amino]carbonyl}-4-methylbenzenesulfonamide;

*N*-{[(2-[4-(2-ethyl-5,7-dimethyl-3*H*-imidazo[4,5-*b*]pyridin-3-yl)phenyl]ethyl)amino]carbonyl}-2-thiophenesulfonamide;

2-[4-(4,6-dimethyl-2-phenyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)phenyl]ethyl (4-methylphenyl)sulfonylcarbamate;

2-[4-(2-butyl-4,6-dimethyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)phenyl]ethyl (4-methylphenyl)sulfonylcarbamate;

2-{4-[4,6-dimethyl-2-(3-phenylpropyl)-1*H*-imidazo[4,5-*c*]pyridin-1-yl]phenyl}ethyl (4-methylphenyl)sulfonylcarbamate;

*N*-{[(2-{4-[5,7-dimethyl-2-(1*H*-pyrazol-3-yl)-3*H*-imidazo[4,5-*b*]pyridin-3-yl]phenyl}ethyl)amino]carbonyl}-4-methylbenzenesulfonamide;

2-{4-[2-(1,1-dimethylethyl)-4,6-dimethyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl]phenyl}ethyl (4-methylphenyl)sulfonylcarbamate; and salts thereof.

10/771,696

-17-

PC9985B

38. (Previously presented) A method according to Claim 28 wherein the compound is selected from

2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-*b*]pyridin-3-yl)phenyl]-1-methylethyl (4-methylphenyl)sulfonylcarbamate;

5,7-dimethyl-3-(4-{2-[{({(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-2-[2-(1,3-thiazol-2-yl)ethyl]-3H-imidazo[4,5-*b*]pyridine;

2-ethyl-5,7-dimethyl-3-(4-{2-[{({(2-thienyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-3H-imidazo[4,5-*b*]pyridine;

3-(4-{2-[{[(2-chlorophenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-*b*]pyridine;

2-ethyl-5,6-dimethyl-3-(4-{2-[{({(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-3H-imidazo[4,5-*b*]pyridine;

5,6-dichloro-2-ethyl-3-(4-{2-[{({(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-3H-imidazo[4,5-*b*]pyridine;

2-ethyl-4,6-dimethyl-1-(4-{2-[{({(4-methylphenyl)sulfonyl]amino}carbonyl)amino]ethyl}phenyl)-1H-imidazo[4,5-*c*]pyridine;

2-[4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-*c*]pyridin-1-yl)phenyl]ethyl (4-methylphenyl)sulfonylcarbamate;

2-{4-[5,7-dimethyl-2-(methylamino)-3H-imidazo[4,5-*b*]pyridin-3-yl]phenyl}ethyl (4-methylphenyl)sulfonylcarbamate;

N-{{(2-{4-[5,7-dimethyl-2-(methylamino)-3H-imidazo[4,5-*b*]pyridin-3-yl]phenyl}ethyl)amino}carbonyl}-4-methylbenzenesulfonamide;

N-[(2-[4-(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-*b*]pyridin-3-yl)phenyl]ethyl)amino]carbonyl]-2-thiophenesulfonamide;

2-[4-(4,6-dimethyl-2-phenyl-1H-imidazo[4,5-*c*]pyridin-1-yl)phenyl]ethyl (4-methylphenyl)sulfonylcarbamate;

10/771,696

-18-

PC9985B

2-[4-(2-butyl)-4,6-dimethyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl]phenyl]ethyl (4-methylphenyl)sulfonylcarbamate;  
2-{4-[4,6-dimethyl-2-(3-phenylpropyl)-1*H*-imidazo[4,5-*c*]pyridin-1-yl]phenyl}ethyl (4-methylphenyl)sulfonylcarbamate;  
*N*-{[(2-{4-[5,7-dimethyl-2-(1*H*-pyrazol-3-yl)-3*H*-imidazo[4,5-*b*]pyridin-3-yl]phenyl}ethyl)amino]carbonyl}-4-methylbenzenesulfonamide;  
2-{4-[2-(1,1-dimethylethyl)-4,6-dimethyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl]phenyl}ethyl (4-methylphenyl)sulfonylcarbamate; and  
salts thereof.

39. (Currently Amended) A method according to claim 28 wherein the compound is

2-ethyl-4,6-dimethyl-1-(4-{2-[(4-methoxyphenyl)sulfonyl]amino}carboxylic acid)phenyl)-1*H*-imidazo[4,5-*Cc*]pyridine or a pharmaceutically acceptable salt thereof.